Currently, the risk of recurrence is assessed by the tumor-node-metastasis (TNM) stage, microsatellite instability/mismatch repair (MSI/MMR) status, number of lymph nodes, and additional clinicopathological characteristics, such as perineural, vascular or lymphatic invasion, histological grade and subtype, tumor obstruction, and levels of carcinoembryonic antigen (CEA) [3]. Here, CEACAM5 is linked to neoplasm.